AstraZeneca today announced that the U.S. FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults …

AstraZeneca reported positive phase 3 trial results of Brilinta (ticagrelor) plus aspirin, which reduced the relative risk of cardiovascular events …

Motivational text messaging may be the key to improving blood sugar control in patients with diabetes and coronary heart disease, according to a new …

Exercise. Improve your diet. Lose weight. You’ve probably heard the mantra over and over again. People living with diabetes know that along …

Following a Mediterranean diet, which includes eating plenty of fruits, vegetables, beans, and good fats, may improve brain function, according to a …

Researchers have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in …

The commonly used diabetes drug metformin could reverse the harmful thickening of the heart muscle that leads to cardiovascular disease, according to …

While investigating why cholesterol-lowering drugs called statins cause negative side effects such as blurred vision, short-term memory loss or …

AstraZeneca’s drug Brilinta® met primary endpoints in Phase 3 trials, the company reported on Monday. The trials showed that Brilinta …

Two drugs commonly prescribed to treat type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or …